The Biologics News and Reports Portal

Show Cart

All Products

Results 121 - 140 of 192

Dec 2014 Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants

1,935.00 €

2,150.00 €

(Discount: 10.00%)

Sep 2014 Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins

200.00 €

Aug 2014 Competitor Analysis: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

350.00 €

Jul 2014 Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders

1,462.50 €

1,950.00 €

(Discount: 25.00%)

Jul 2014 Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors

200.00 €

Jun 2014 Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors

200.00 €

Mar 2014 Competitor Analysis: Cancer Vaccines

800.00 €

Mar 2014 2013 Sales of Recombinant Therapeutic Antibodies & Proteins

25.00 €

Jan 2014 Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis

2,150.00 €

Jan 2014 Competitor Analysis: Immunocytokines

250.00 €

Nov 2013 Competitor Analysis: Janus Kinase (JAK) and spleen tyrosine kinase (syk) Inhibitors

400.00 €

Oct 2013 Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives)

500.00 €

Oct 2013 The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

1,450.00 €

Sep 2013 Competitor Analysis: Pim Kinase Inhibitors

150.00 €

Shopping cart

Cart empty

Latest report

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Featured Products

Report bundle: Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Shopping cart

Cart empty

Latest report

Featured Products

Report bundle: Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

All Products

Dec 2014 Recombinant Coagulation Factors 2015: Maturation of recombinant clotting factor pipeline and emergence of gene therapy and alternative procoagulants

Nov 2014 Competitor Analysis: Cancer Peptides

Nov 2014 Competitor Analysis: Cardiometabolic Peptides

Oct 2014 Competitor Analysis: Ebola Virus Vaccines and Therapeutics

Oct 2014 Competitor Analysis: Anti-Infective Peptides

Oct 2014 Competitor Analysis: Cardiovascular Peptides

Sep 2014 Competitor Analysis: Anti-Inflammatory Peptides

Sep 2014 Competitor Analysis: Rabies Virus Vaccines, Antibodies and Immune Globulins

Aug 2014 Competitor Analysis: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Jul 2014 Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders

Jul 2014 Competitor Analysis: alpha1-Proteinase Inhibitors (alpha1-PI), alpha1-Antitrypsin (AAT) and Elastase Inhibitors

Jun 2014 Competitor Analysis: Phosphodiesterase 4 (PDE-4) Inhibitors

Mar 2014 Competitor Analysis: Cancer Vaccines

Mar 2014 2013 Sales of Recombinant Therapeutic Antibodies & Proteins

Jan 2014 Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis

Jan 2014 Competitor Analysis: Immunocytokines

Nov 2013 Competitor Analysis: Janus Kinase (JAK) and spleen tyrosine kinase (syk) Inhibitors

Oct 2013 Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives)

Oct 2013 The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

Sep 2013 Competitor Analysis: Pim Kinase Inhibitors

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing